The role of local and systemic inflammation in inflammatory bowel disease, autoimmune disease, and cardiometabolic disease.

Recruiting

• Conditions: K52; I10; E11; G35; Other noninfective gastroenteritis and colitis; Essential (primary) hypertension; Type 2 diabetes mellitus; Multiple sclerosis

• Registration Number: DRKS00031203
• Lead Sponsor: Charité - Universitätsmedizin Berlin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-02-10
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Disease definition according to guidelines:
- IBD, histologically confirmed
- Diabetes: diabetes mellitus type 2 with or without insulin therapy
- MS: Diagnosis according to McDonald 2017, Ref. Thompson et al. Lancet neurol 2017
- Hypertension: Unger et al 2020 '2020 International Society of Hypertension Global Hypertension Practice Guidelines' Hypertension. 2020;75:1334-1357

Exclusion Criteria

- Refusal to participate in the study
- Lack of capacity to give consent
- Pregnancy and/or active breastfeeding

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Immune/cytokine, metabolite, or proteomic signatures from mucosal interstitial fluids (IF), intestinal biopsies, and blood measured by mass spectrometry (CyTOF), CyTOF/imaging, or flow cytometry or ELISA or cytometric bead arrays or OLINK, respectively